Ejection fraction preserved heart failure and microvascular endothelial inflammation
-
摘要: 射血分数保留型心力衰竭(HFpEF)是一种以运动耐受减低和组织充血为特征的临床综合征,其原因主要有炎症反应、内皮功能障碍、代谢异常等。临床上还未出现治疗HFpEF的有效药物,其发病机制也尚未明确,目前提出的微血管内皮炎症有望成为重要靶点。HFpEF并发症导致全身炎症反应,随后冠状动脉微血管内皮细胞氧化应激,降低心肌细胞的一氧化氮(NO)生物利用度,导致心肌细胞环磷酸鸟苷(cGMP)-蛋白激酶G(PKG)活性降低,引起心肌顺应性降低和心肌肥厚。本文就此作一综述。Abstract: Ejection fraction preserved heart failure(HFpEF) is a clinical syndrome characterized by reduced exercise tolerance and hyperemia, mainly caused by the inflammatory response, endothelial dysfunction, and metabolic abnormalities. Unfortunately, there is no effective drug for the treatment of HFpEF in clinical practice, and the pathogenesis of HFpEF is still unclear. Currently, the proposed microvascular endothelial inflammation is expected to become an important target. Complications of HFpEF lead to systemic inflammation, followed by oxidative stress of coronary microvascular endothelial cells. In addition, microvascular endothelial inflammation can decrease the bioavailability of nitric oxide(NO), and the activity of cGMP-protein kinase G(PKG), resulting in decreased myocardial compliance and hypertrophy. This review will summarize the pathogenesis of systemic inflammation and microvascular endothelial inflammation in HFpEF.
-
-
[1] 卢永昕.HFpEF精准医疗时代到来了吗?[J].临床心血管病杂志,2019,35(4):295-296.
[2] Pfeffer MA,Shah AM,Borlaug BA.Heart failure with preserved ejection fraction in perspective[J].Circ Res,2019,124(11):1598-1617.
[3] 刘文豪,石榴,李彬,等.射血分数保留的心力衰竭患者运动耐量减低的非舒张机制[J].临床心血管病杂志,2020,36(12):1150-1154.
[4] 壮可,张宏,赵燕,等.射血分数保留的心力衰竭患者心脏变时功能不全与运动耐量及预后的关系[J].临床心血管病杂志,2019,35(5):453-457.
[5] Duque ER,Briasoulis A,Alvarez PA.Heart failure with preserved ejection fraction in the elderly:pathophysiology,diagnostic and therapeutic approach[J].J Geriatr Cardiol,2019,16(5):421-428.
[6] Iliesiu AM,Hodorogea AS.Treatment of heart failure with preserved ejection fraction[J].Adv Exp Med Biol,2018,1067:67-87.
[7] 刘莉,叶鹏,Gevaert AB,等.老龄小鼠模型内皮细胞衰老导致射血分数保留的心力衰竭[J].中华高血压杂志,2017,25(9):859.
[8] Chadderdon SM,Belcik JT,Bader L,et al.Proinflammatory endothelial activation detected by molecular imaging in obese nonhuman primates coincides with onset of insulin resistance and progressively increases with duration of insulin resistance[J].Circulation,2014,129(4):471-478.
[9] Lin QY,Lang PP,Zhang YL,et al.Pharmacological blockage of ICAM-1 improves angiotensin II-induced cardiac remodeling by inhibiting adhesion of LFA-1+ monocytes[J].Am J Physiol Heart Circ Physiol,2019,317(6):H1301-H1311.
[10] Bayes-Genis A,Bisbal F,Núňez J,et al.Transitioning from preclinical to clinical heart failure with preserved ejection fraction:a mechanistic approach[J].J Clin Med,2020,9(4).
[11] Paulus WJ,Tschöpe C.A novel paradigm for heart failure with preserved ejection fraction:comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation[J].J Am Coll Cardiol,2013,62(4):263-271.
[12] Juni RP,Kuster D,Goebel M,et al.Cardiac microvascular endothelial enhancement of cardiomyocyte function Is impaired by inflammation and restored by empagliflozin[J].JACC Basic Transl Sci,2019,4(5):575-591.
[13] Franssen C,Chen S,Unger A,et al.Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction[J].JACC Heart Fail,2016,4(4):312-324.
[14] Meagher P,Adam M,Civitarese R,et al.Heart failure with preserved ejection fraction in diabetes:mechanisms and management[J].Can J Cardiol,2018,34(5):632-643.
[15] 徐建清.被动腿部运动改善射血分数保留心衰大鼠血管内皮功能[D].南昌:南昌大学第二附属医院,2018:1-38.
[16] 周福亮,贾大林.射血分数保留性心力衰竭与内皮功能障碍[J].中国老年学杂志,2018,38(19):4852-4855.
[17] Akiyama E,Sugiyama S,Matsuzawa Y,et al.Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction[J].J Am Coll Cardiol,2012,60(18):1778-1786.
[18] Lyle MA,Brozovich FV.HFpEF,a disease of the vasculature:a closer look at the other half[J].Mayo Clin Proc,2018,93(9):1305-1314.
[19] Lam CS,Lund LH.Microvascular endothelial dysfunction in heart failure with preserved ejection fraction[J].Heart,2016,102(4):257-259.
[20] Grumbach IM,Chen W,Mertens SA,et al.A negative feedback mechanism involving nitric oxide and nuclear factor kappa-B modulates endothelial nitric oxide synthase transcription[J].J Mol Cell Cardiol,2005,39(4):595-603.
[21] Lai TS,Lindberg RA,Zhou HL,et al.Endothelial cell-surface tissue transglutaminase inhibits neutrophil adhesion by binding and releasing nitric oxide[J].Sci Rep,2017,7(1):16163.
[22] Henning RJ.Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction[J].World J Cardiol,2020,12(1):7-25.
[23] Glezeva N,Voon V,Watson C,et al.Exaggerated inflammation and monocytosis associate with diastolic dysfunction in heart failure with preserved ejection fraction:evidence of M2 macrophage activation in disease pathogenesis[J].J Card Fail,2015,21(2):167-177.
[24] Polsinelli VB,Shah SJ.Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction:an ideal opportunity for precision medicine[J].Expert Opin Pharmacother,2017,18(4):399-409.
[25] Takahama H,Asakura M,Abe Y,et al.Rationale and design of the multicenter trial on Japan working group on the effects of angiotensin receptor blockers selection(Azilsartan vs.Candesartan)on diastolic function in the patients suffering from heart failure with preserved ejection fraction:J-TASTE Trial[J].Cardiovasc Drugs Ther,2018,32(4):381-388.
[26] Kjeldsen SE,von Lueder TG,Smiseth OA,et al.Medical therapies for heart failure with preserved ejection fraction[J].Hypertension,2020,75(1):23-32.
[27] Lam PH,Packer M,Gill GS,et al.Digoxin initiation and outcomes in patients with heart failure with preserved ejection fraction[J].Am J Med,2020,133(10):1187-1194.
[28] Nadeem M,Hassib M,Aslam HM,et al.Role of ivabradine in patients with heart failure with preserved ejection fraction[J].Cureus,2020,12(2):e7123.
[29] Wang H,Anstrom K,Ilkayeva O,et al.Sildenafil treatment in heart failure with preserved ejection fraction:targeted metabolomic profiling in the RELAX trial[J].JAMA Cardiol,2017,2(8):896-901.
[30] Redfield MM,Anstrom KJ,Levine JA,et al.Isosorbide mononitrate in heart failure with preserved ejection fraction[J].N Engl J Med,2015,373(24):2314-2324.
[31] Redfield MM,Borlaug BA,Lewis GD,et al.PhosphdiesteRasE-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure(RELAX)trial:rationale and design[J].Circ Heart Fail,2012,5(5):653-659.
[32] Cunningham JW,Vaduganathan M,Claggett BL,et al.Effects of sacubitril/valsartan on N-terminal pro-B-type natriuretic peptide in heart failure with preserved ejection fraction[J].JACC Heart Fail,2020,8(5):372-381.
[33] Armstrong PW,Lam C,Anstrom KJ,et al.Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction:The VITALITY-HFpEF Randomized Clinical Trial[J].JAMA,2020,324(15):1512-1521.
[34] Halabi A,Sen J,Huynh Q,et al.Metformin treatment in heart failure with preserved ejection fraction:a systematic review and meta-regression analysis[J].Cardiovasc Diabetol,2020,19(1):124.
[35] 李芊,于子翔,马依彤.他汀类药物在射血分数保留的心力衰竭中的治疗进展[J].中国心血管病研究,2019,17:9-12.
[36] Reddy Y,Obokata M,Koepp KE,et al.The β-adrenergic agonist albuterol improves pulmonary vascular reserve in heart failure with preserved ejection fraction[J].Circ Res,2019,124(2):306-314.
[37] Kolijn D,Pabel S,Tian Y,et al.Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation[J].Cardiovasc Res,2021,117(2):495-507.
-
计量
- 文章访问数: 459
- PDF下载数: 256
- 施引文献: 0
下载: